5 Einträge gefunden

1. Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry

   1. Kany, Shinwan
   2. Brachmann, Johannes
   3. Lewalter, Thorsten
   4. Akin, Ibrahim
   5. Sievert, Horst
   6. Zeymer, Uwe
   7. Ledwoch, Jakob

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Influence of severe anemia on procedural safety and one-year outcome after left atrial appendage closure: Insights from a very high-risk cohort

   1. Kany, Shinwan
   2. Brachmann, Johannes
   3. Lewalter, Thorsten
   4. Akin, Ibrahim
   5. Sievert, Horst
   6. Zeymer, Uwe
   7. Hochadel, Matthias

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial

   1. Karakas, Mahir
   2. Akin, Ibrahim
   3. Burdelski, Christoph
   4. Clemmensen, Peter
   5. Grahn, Hanno
   6. Jarczak, Dominik
   7. Keßler, Mirjam

   2022 - Forschungsinformationssystem des UKE
4. Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial

   1. Thiele, Holger
   2. Freund, Anne
   3. Gimenez, Maria Rubini
   4. de Waha-Thiele, Suzanne
   5. Akin, Ibrahim
   6. Pöss, Janine
   7. Feistritzer, Hans-Josef

   2021 - Forschungsinformationssystem des UKE
5. The ACCOST-HH Trial:An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed

   1. Skurk, Carsten
   2. Rottbauer, Wolfgang
   3. Kessler, Mirjam
   4. Akin, Ibrahim
   5. Kluge, Stefan
   6. Burdelski, Christoph
   7. Blankenberg, Stefan

   2020 - Forschungsinformationssystem des UKE